3 ML insulin glargine-aglr 100 UNT/ML Pen Injector
Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.
Start free with EleplanClinical drug
3 ML insulin glargine-aglr 100 UNT/ML Pen Injector
100 UNT/ML · Pen Injector · injection
A form of insulin glargine-aglr →
3 ML insulin glargine-aglr 100 UNT/ML Pen Injector — Insulins and analogues for injection, long-acting. Strength, form, class, interactions & more.
Active ingredient
Classification
Insulins and analogues for injection, long-actingInsulin Analog
Drug interactions
Insulin glargine-aglr has several clinically significant drug interactions that may affect blood glucose levels.
- moderateantidiabetic agents — may increase the risk of hypoglycemia
- moderateACE inhibitors — may increase the risk of hypoglycemia
- moderateangiotensin II receptor blocking agents — may increase the risk of hypoglycemia
- moderatedisopyramide — may increase the risk of hypoglycemia
- moderatefibrates — may increase the risk of hypoglycemia
- moderatefluoxetine — may increase the risk of hypoglycemia
- moderatemonoamine oxidase inhibitors — may increase the risk of hypoglycemia
- moderatepentoxifylline — may increase the risk of hypoglycemia
- moderatepramlintide — may increase the risk of hypoglycemia
- moderatesalicylates — may increase the risk of hypoglycemia
- moderatesomatostatin analogs (e.g., octreotide) — may increase the risk of hypoglycemia
- moderatesulfonamide antibiotics — may increase the risk of hypoglycemia
- moderateGLP-1 receptor agonists — may increase the risk of hypoglycemia
- moderateDPP-4 inhibitors — may increase the risk of hypoglycemia
- moderateSGLT-2 inhibitors — may increase the risk of hypoglycemia
- moderateatypical antipsychotics (e.g., olanzapine and clozapine) — may decrease the blood glucose lowering effect
- moderatecorticosteroids — may decrease the blood glucose lowering effect
- moderatedanazol — may decrease the blood glucose lowering effect
- moderatediuretics — may decrease the blood glucose lowering effect
- moderateestrogens — may decrease the blood glucose lowering effect
- moderateglucagon — may decrease the blood glucose lowering effect
- moderateisoniazid — may decrease the blood glucose lowering effect
- moderateniacin — may decrease the blood glucose lowering effect
- moderateoral contraceptives — may decrease the blood glucose lowering effect
- moderatephenothiazines — may decrease the blood glucose lowering effect
- moderateprogestogens (e.g., in oral contraceptives) — may decrease the blood glucose lowering effect
- moderateprotease inhibitors — may decrease the blood glucose lowering effect
- moderatesomatropin — may decrease the blood glucose lowering effect
- moderatesympathomimetic agents (e.g., albuterol, epinephrine, terbutaline) — may decrease the blood glucose lowering effect
- moderatethyroid hormones — may decrease the blood glucose lowering effect
- moderatealcohol — may increase or decrease the blood glucose lowering effect
- moderatebeta-blockers — may increase or decrease the blood glucose lowering effect and blunt signs and symptoms of hypoglycemia
- moderateclonidine — may increase or decrease the blood glucose lowering effect and blunt signs and symptoms of hypoglycemia
- moderatelithium salts — may increase or decrease the blood glucose lowering effect
- unknownpentamidine — may cause hypoglycemia, which may sometimes be followed by hyperglycemia
- unknownguanethidine — may blunt signs and symptoms of hypoglycemia
- unknownreserpine — may blunt signs and symptoms of hypoglycemia
Real-world adverse events (FAERS)
Accidental Underdose13Blood Glucose Increased11Product Dose Omission Issue8Drug Ineffective6Incorrect Dose Administered5Injection Site Haemorrhage4Inappropriate Schedule of Product Administration3Incorrect Product Administration Duration3
Source: RxNorm + openFDA + RxClass + FAERS · 2026
Look up another medication